This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Acute myeloid leukemia (AML); B cell acute lymphoblastic lymphoma (B-ALL)	Cluster of differentiation 1C (CD1C)	<p>Cell culture and mouse studies suggest methyl-lysophosphatidic acids presented by CD1C could be useful for stimulating immune response against AML and B-ALL. <i>In vitro</i>, synthetic analogs of methyl-lysophosphatidic acids bound to CD1C on AML and B-ALL cells and resulted in a stronger T cell response than vehicle. In a mouse xenograft model of AML, T cells primed with methyl-lysophosphatidic acids decreased tumor growth and improved survival compared with unprimed T cells. Next steps could include developing autologous transplantation protocols to prime therapeutic T cells to react against tumor-derived lipids such as methyl-lysophosphatidic acids.</p> <p>SciBX 7(29); doi:10.1038/scibx.2014.853 Published online July 31, 2014</p>	Patent and licensing status undisclosed	<p>Lepore, M. <i>et al. J. Exp. Med.</i>; published online June 16, 2014; doi:10.1084/jem.20140410 Contact: Gennaro De Libero, University of Basel, Basel, Switzerland e-mail: gennaro.delibero@unibas.ch Contact: Lucia Mori, same affiliation as above e-mail: lucia.mori@unibas.ch Contact: Giulia Casorati, San Raffaele Scientific Institute, Milan, Italy e-mail: casorati.giulia@hsr.it Contact: Paolo Dellabona, same affiliation as above e-mail: dellabona.paolo@hsr.it</p>